ClinicalTrials.gg
Not yet recruitingNCT07949474Updated Nov 19, 2026

Semaglutide in Alcohol Use Disorder

A Phase 3 interventional study of Wegovy and Placebo in Alcohol Use Disorder (AUD) and Obesity, sponsored by University of Minnesota. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by University of Minnesota · Phase 3, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
128
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 1,075 studies in Alcoholism with a site in United States — 189 open to participants now, 229 under way, 16 of them phase 3. Alcoholism · United States.

Planned enrollment
336th of 991
128 · median 80
Started
2027
with 12 others
Phase 3
49 of 1,075
8 open now
Primary completion
2032-04
later than 221 of 228 live
Registered
1,075th of 1,075
by date

Among the 1,075 studies in Alcoholism with a site in United States, this one is the 336th largest by planned enrollment of the 991 interventional ones that give a count, is one of 13 that started in 2027, is one of 49 in phase 3, reaches primary completion later than 221 of the 228 other live ones, and was the 1,075th registered.

Alcoholism

1,678 studies on the registry are indexed under Alcoholism; 332 are open to participants now.

Browse Alcoholism studies →

Open to participants now

189 of the 1,075 studies in Alcoholism with a site in United States are open now. Recruiting first, the newest first:

184 more — sign in →

All 189 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 239 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 132 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,075 studies in Alcoholism with a site in United States, or all of them as a file.
02

Study summary

This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes among 128 adults with alcohol use disorder (AUD) and obesity.

Read the detailed description

This is a 45-week, randomized, double-blind, placebo-controlled clinical trial designed to compare the effectiveness of semaglutide versus placebo on alcohol-related outcomes (alcohol intake, cravings, self-control, affect, quality of life, physiologic data; collected using validated questionnaires and in one's natural environments using ecological momentary assessment (EMA) and wearable devices [i.e., activity/health trackers]) among 128 adults (18 to 65 years old) with alcohol use disorder (AUD) and obesity (body mass index (BMI) >/= 30). We also seek to develop personal causal models for alcohol use and urges.

03

Conditions studied

  • Alcohol Use Disorder (AUD)
  • Obesity
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-65 years
  • Meet (DSM-5) criteria for mild or moderate AUD
  • >/=1 bout of heavy drinking (defined as >/= 4 drinks/day for females; >/= 5 drinks/day for males) within the last month
  • Have an interest in reducing or quitting alcohol intake
  • Have obesity (defined as >/= 30 kg/m2) at screening
  • Ability to provide before any trial-related activities

Exclusion criteria

Exclusion Criteria:

  • Impaired ability to provide consent to a clinical trial and/or comply with study procedures and/or measures using a smartphone (e.g., intellectual disability, acute intoxication, etc.)
  • Meet (DSM-5) criteria for Severe AUD
  • Lifetime diagnosis of psychosis and/or bipolar-spectrum disorders
  • Serious withdrawal symptoms defined as a score higher than 9 on Clinical Institute Withdrawal Assessment (CIWA) for Alcohol Scale, Revised at the baseline visit
  • Current or history of neurological disease including traumatic brain injury
  • Diagnosis of type 1 diabetes mellitus
  • Diagnosis of type 2 diabetes mellitus with A1c >/= 10% or type 2 diabetes mellitus on insulin therapy
  • Current hyperthyroidism or uncontrolled hypothyroidism
  • Current pregnancy or breast-feeding, plans to become pregnant within the next 12 months, or if sexually active refusal to use adequate measures
  • Impaired hepatic function ( (AST)or alanine aminotransferase (ALT) > 3 times upper normal limit
  • Impaired renal function (estimated (eGFR)\< 50 mL/minute
  • Known to semaglutide
  • Any history of pancreatitis (acute or chronic; for semaglutide)
  • Triglycerides >/= 1000 mg/dL
  • History of medullary thyroid carcinoma (MTC) and/or family history with MTC and/or multiple endocrine neoplasia syndrome type 2 (contraindication for semaglutide)
  • Uncontrolled hypertension (systolic blood pressure > 180 mm Hg; diastolic blood pressure > 110 mm Hg)
  • Concomitant pharmacotherapy for alcohol dependence (e.g. disulfiram, naltrexone, acamprosate) or treatment with any of these within 1 month prior to screening visit
  • Current or recent (\< 6 months prior to screening) use of weight loss medication(s) (e.g., phentermine, Glucagon-Like Peptide-1 Receptor Agonist (GLP1-RAs)) or other weight altering medication(s) (e.g., atypical anti-psychotics), unless dose(s) of these have been stable for >6 months from screening
  • Any condition that the investigator feels would interfere with trial participation
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
128 participants (estimated)

Study arms

  • Active comparator
    Semaglutide

    Participants in this arm of the study will receive semaglutide (the study drug)

    Drug: Wegovy

  • Placebo comparator
    Placebo

    Participants in this arm will receive placebo

    Other: Placebo

Interventions

  • DrugWegovy

    Participants in this arm will receive 42 weeks of treatment with semaglutide

  • OtherPlacebo

    Participants in this arm will receive 42 weeks of placebo

06

What researchers measure

Primary outcomes

  1. Heavy drinking days

    Number of heavy drinking days

    Time frame: Randomization to Week 45

  2. Total drinking days

    Total number of drinking days

    Time frame: Randomization to Week 45

07

Study locations

1 site
  • University of Minnesota Center for Pediatric Obesity Medicine
    Minneapolis, Minnesota 55414, United States
    • Eric Bomberg, MD · Contactbombe002@umn.edu · (612) 626-2349
    • Eric Bomberg, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: Yes — De-identified study data will be shared upon completion of a data use agreement

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: April 30, 2033 (start date) April 30, 2037 (end date)

Access criteria: Interested parties should contact Dr. Bomberg to start the process of starting a data use agreement

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2027; primary completion for Apr 2032, 59 months later.

Of 25 phase 3 interventional studies under Alcoholism, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 59 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2026
First posted
Nov 19, 2026
StartEst.
May 1, 2027
Primary completionEst.
Apr 30, 2032
CompletionEst.
Apr 30, 2033
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07949474
Responsible party
Eric Bomberg (Principal Investigator, University of Minnesota) — Principal investigator
First posted
Nov 19, 2026
Start date
May 1, 2027 (estimated)
Primary completion
Apr 30, 2032 (estimated)
Completion
Apr 30, 2033 (estimated)
Last update
Nov 19, 2026

Study contacts

Eric Bomberg, MD
Contact
bombe002@umn.edu
(612) 626-2349
Eric Bomberg, MD
principal investigator · University of Minnesota

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion